SecBot SecBot
6-K ·Filed Aug 4, 2026

SNN

SMITH & NEPHEW PLC
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001654954-26-007206
Notable filing: 6-K
Actionable Insight ◆ Mixed

The revenue miss and guidance cut are concerning, but the strong profit growth and maintained profit/FCF guidance suggest cost controls are working. Watch the Q3 trading report on Nov 6 for signs of revenue acceleration in H2, particularly in US Orthopaedics and Advanced Wound Bioactives. The buyback provides a floor, but the stock may remain range-bound until revenue momentum improves.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$30.44
T+0 close · Aug 4, 2026 · via day close
Latest settled
−1.12%
T+60 · $30.10
Vs SPY
−1.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $30.44entry
  2. T+1 · 3mo ago −1.02%α −0.82% · $30.13
  3. T+5 · 3mo ago −1.41%α −1.31% · $30.01
  4. T+20 · 3mo ago −4.83%α −3.59% · $28.97
  5. T+60 · 20d ago −1.12%α −1.49% · $30.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying) and trading profit of $566M (+8.1%), beating profit expectations but missing revenue targets. Full-year revenue guidance was cut from ~6% to ~4%, though trading profit, free cash flow, and ROIC guidance were maintained. The $500M share buyback is underway ($216M settled) and the interim dividend was raised 4% to 15.6¢ per share.

Key Facts

  • H1 2026 revenue $3,097M, underlying growth 2.3% (reported +4.6% incl. 230bps FX tailwind)
  • Q2 2026 revenue $1,597M, underlying growth 1.6% (reported +2.8%)
  • Trading profit $566M, up 8.1% reported; trading margin +60bps to 18.3%
  • EPSA up 11.0% to 47.7¢; basic EPS up 6.2% to 35.6¢
  • Full-year revenue guidance lowered from ~6% to ~4%; trading profit, FCF, ROIC guidance unchanged
  • $500M share buyback announced May 2026, $216M settled as of Aug 3
  • Interim dividend increased 4.0% to 15.6¢ per share
  • Net debt $3,019M, adjusted leverage 1.8x; $4.7B committed facilities

Financial Impact

Revenue growth missed expectations by ~2pp (guidance cut from 6% to 4%), but trading profit grew 8.1% and margins expanded 60bps. The $500M buyback and 4% dividend increase provide shareholder return support.

revenuetrading profitEPSfree cash flownet debt

Risk Factors

  • US Orthopaedics weakness (Knee Implants -7.2%, Hip Implants -1.5% in Q2) may persist
  • Advanced Wound Bioactives revenue declined -12.7% underlying in Q2 due to reimbursement changes
  • Full-year revenue guidance cut implies H2 growth must accelerate to 5.0-5.5%, execution risk
  • Skin substitutes headwind expected at upper end of $20-40M range

Market Snapshot

Exchange
OTC
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
50% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007206
Document: 0001654954-26-007206-index-headers.html0001654954-26-007206
Document: 0001654954-26-007206-index.html0001654954-26-007206
Document: 0001654954-26-007206.txt0001654954-26-007206

Track record

42 reports on SNN

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
  2. Nov 4, 202612d ago 6-K Bearish 6/10 No price data
  3. Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
  4. Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
  5. Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
  6. Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
  7. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  8. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  9. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
  10. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
Showing 10 of 42

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026